The deal will not be finalized until approved by Exact Sciences’ shareholders. With it, Abbott gains control of new diagnostic tools, including a popular at-home test for colorectal cancer.
The U.S. Food and Drug Administration has green-lit new updates that improve microvascular flow, AI-assisted harmonic imaging and elastography, which Canon will showcase at RSNA 2025.
The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.
One of the AI haves feels the pain of the AI have-nots.His discomfort is especially pronounced when he thinks about how hard it must be for financial strugglers to keep up with regulations and rumors of regulations to come.
It's slated to become the 31st state to finalize legislation eliminating out-of-pocket costs for follow-up exams after an abnormal screening mammogram.
The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.”
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?
According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials.
The deal will not be finalized until approved by Exact Sciences’ shareholders. With it, Abbott gains control of new diagnostic tools, including a popular at-home test for colorectal cancer.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
